- $65.72m
- $18.58m
- $1.00m
- 61
- 22
- 57
- 44
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.14 | ||
| Price to Tang. Book | 1.5 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 68.17 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -16.68% | ||
| Return on Equity | -13.18% | ||
| Operating Margin | -1007.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 4.04 | n/a | 1 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
Directors
- Jeffrey Himawan NEC (56)
- Yuichi Iwaki PRE (71)
- Douglas Paulin CFO (46)
- Geoffrey O'brien VPR (52)
- Kazuko Matsuda OTH (55)
- Carolyn Beaver IND (63)
- Hideki Nagao IND (64)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- September 26th, 2000
- Public Since
- December 1st, 2006
- No. of Shareholders
- 11
- No. of Employees
- 13
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 49,046,246
- Address
- SUITE 650, 4275 EXECUTIVE SQUARE, LA JOLLA, 92037
- Web
- https://medicinova.com/
- Phone
- +1 8583731500
- Auditors
- BDO USA, LLP
Upcoming Events for MNOV
Q3 2024 MediciNova Inc Earnings Release
Similar to MNOV
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Medicinova share price?
As of Today at 22:00 UTC, shares in Medicinova are trading at $1.39. This share price information is delayed by 15 minutes.
How has the Medicinova share price performed this year?
Shares in Medicinova last closed at $1.39 and the price had moved by -42.8% over the past 365 days. In terms of relative price strength the Medicinova share price has underperformed the S&P500 Index by -54.48% over the past year.
What are the analyst and broker recommendations for Medicinova?
The overall consensus recommendation for Medicinova is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Medicinova dividend yield?
Medicinova does not currently pay a dividend.
Does Medicinova pay a dividend?
Medicinova does not currently pay a dividend.
When does Medicinova next pay dividends?
Medicinova does not currently pay a dividend.
How do I buy Medicinova shares?
To buy shares in Medicinova you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Medicinova?
As of the previous close price of $1.39, shares in Medicinova had a market capitalisation of $68.17m.
Where are Medicinova shares listed?
Here are the trading details for Medicinova:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: MNOV
What kind of share is Medicinova?
Based on an overall assessment of its quality, value and momentum Medicinova is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Medicinova share price forecast for 2024?
The analyst consensus target price for shares in Medicinova is $16.00. That is 1051.08% above the last closing price of $1.39.
Analysts covering Medicinova currently have a consensus Earnings Per Share (EPS) forecast of -$0.23 for the next financial year.
What is the trend in the Medicinova share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medicinova. Over the past six months, its share price has underperformed the S&P500 Index by -16.81%.
As of the last closing price of $1.39, shares in Medicinova were trading -13.22% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Medicinova PE Ratio?
The Medicinova PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.39.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Medicinova?
Medicinova's management team is headed by:
- Jeffrey Himawan - NEC
- Yuichi Iwaki - PRE
- Douglas Paulin - CFO
- Geoffrey O'brien - VPR
- Kazuko Matsuda - OTH
- Carolyn Beaver - IND
- Hideki Nagao - IND